LivaNova (NASDAQ:LIVN) Rating Lowered to Hold at StockNews.com

StockNews.com downgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a hold rating in a research report released on Wednesday morning.

A number of other equities research analysts have also recently issued reports on the company. Needham & Company LLC restated a buy rating and set a $72.00 price objective on shares of LivaNova in a report on Wednesday, March 20th. Barclays lifted their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a research report on Monday, February 26th. Robert W. Baird lifted their price target on shares of LivaNova from $56.00 to $62.00 and gave the company a neutral rating in a research report on Thursday, February 22nd. Finally, Mizuho reiterated a buy rating and issued a $75.00 price target on shares of LivaNova in a research report on Wednesday, March 27th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of $64.40.

LivaNova Trading Down 0.8 %

Shares of NASDAQ:LIVN opened at $52.33 on Wednesday. LivaNova has a 12-month low of $42.75 and a 12-month high of $59.86. The stock has a market cap of $2.82 billion, a PE ratio of 163.54 and a beta of 0.89. The business has a 50 day moving average of $53.58 and a 200-day moving average of $50.54. The company has a quick ratio of 2.51, a current ratio of 2.95 and a debt-to-equity ratio of 0.44.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The company had revenue of $310.10 million during the quarter, compared to analysts’ expectations of $287.65 million. During the same quarter in the previous year, the company posted $0.81 earnings per share. The business’s revenue was up 12.8% on a year-over-year basis. As a group, equities research analysts forecast that LivaNova will post 3.01 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Lazard Asset Management LLC acquired a new position in LivaNova during the second quarter valued at approximately $46,000. Point72 Middle East FZE acquired a new position in LivaNova during the fourth quarter valued at approximately $72,000. Headlands Technologies LLC acquired a new position in LivaNova during the third quarter valued at approximately $72,000. Picton Mahoney Asset Management acquired a new position in LivaNova during the third quarter valued at approximately $91,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of LivaNova by 16.7% during the second quarter. PNC Financial Services Group Inc. now owns 2,853 shares of the company’s stock worth $147,000 after buying an additional 408 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.